Amgen Psoriasis nominee Impresses Zacks.com The brand-new England Journal of medical science recently published positive state of matter II data on Amgen's (AMGN) psoriasis candidate, brodalumab (formerly known as AMG 827). Results from the 12-week randomized, double-blind, placebo-controlled, dose-ranging phase II ... Brodalumab For Moderate To Severe Psoriasis Moving Into Phase III Medical tidings Today all 4 tidings articles » Link To Article
No comments:
Post a Comment